Category rating scales for amount of symptoms at weeks 4, 8 and 12
| Week 4 | Week 8 | Week 12 | ||||
| Cannabis extract | Placebo | Cannabis extract | Placebo | Cannabis extract | Placebo | |
| Questionnaire | x̄±SD | x̄±SD | x̄±SD | x̄±SD | x̄±SD | x̄±SD |
| CRS* | ||||||
| Muscle stiffness | 5.3±2.2 | 6.1±2.3 | 5.3±2.3 | 6.2±2.6 | 5.4±2.6 | 6.4±2.6 |
| Body pain | 3.9±2.6 | 4.5±3.0 | 4.1±2.8 | 4.6±3.2 | 4.1±2.9 | 4.7±3.0 |
| Muscle spasms | 4.5±2.6 | 6.1±2.7 | 4.6±2.5 | 5.1±2.8 | 4.7±2.7 | 5.4±2.8 |
| Sleep quality | 3.6±2.6 | 4.5±3.0 | 3.8±2.7 | 4.3±2.9 | 3.8±2.9 | 4.3±3.0 |
| MSSS-88† | ||||||
| Muscle stiffness | 30.3±8.3 | 32.9±9.0 | – | – | 31.8±9.6 | 34.2±9.2 |
| Pain/discomfort | 21.0±7.0 | 21.7±7.5 | – | – | 21.7±7.6 | 22.5±7.6 |
| Muscle spasms | 27.9±10.2 | 28.8±11.1 | – | – | 29.1±11.0 | 30.5±12.1 |
| Daily activities | 30.1±9.3 | 31.0±9.1 | – | – | 31.4±10.1 | 31.4±9.4 |
| Ability to walk | 31.2±8.4 | 33.3±6.5 | – | – | 31.6±7.9 | 34.2±6.7 |
| Body movement | 29.3±9.2 | 30.1±8.8 | – | – | 30.0±10.0 | 31.2±9.0 |
| Feelings | 29.4±12.0 | 29.6±11.9 | – | – | 30.9±11.9 | 30.7±12.2 |
| Social functioning | 17.0±7.41 | 17.4±6.8 | – | – | 18.1±7.6 | 17.6±7.2 |
| MSIS-29† | ||||||
| Physical impact | 58.1±24.1 | 59.8±22.7 | – | – | 58.6±25.7 | 62.4±22.7 |
| Psychological impact | 38.7±25.7 | 38.5±26.6 | – | – | 42.0±27.5 | 40.4±24.4 |
| MSWS-12‡ | ||||||
| Total score | 81.9±22.6 | 87.6±15.5 | – | – | 78.7±26.2 | 89.6±14.6 |
↵* Assessed by an 11 point numerical Likert scale (0=no symptom expression, …, 10=extreme symptom expression).
↵† Possible answers: 1, not at all bothered/limited; 2, a little bothered/limited; 3, moderately bothered/limited; 4, extremely bothered/limited.
↵‡ Possible answers: 1, not at all; 2, a little; 3, moderately; 4, quite a bit; 5, extremely.
CRS, category rating scale; MSIS-29, Multiple Sclerosis Impact Scale; MSSS-88, Multiple Sclerosis Spasticity Scale; MSWS-12, Multiple Sclerosis Walking Scale; N, number of patients in specified group; x̄, mean symptom score.